Skin cancer is the most common form of cancer in the United States and remains a major source of morbidity and mortality despite advances in screening and treatment. Early detection and appropriate risk-adjusted treatment are essential to ensure optimal patient outcomes, but diagnosis and staging of common skin cancers such as melanoma and cutaneous squamous cell carcinoma (cSCC) can be challenging. In recent years, novel technologies have emerged that can aid in the early detection of patients with high-risk disease who might require a more aggressive treatment approach. To help dermatologists accurately diagnose and effectively treat such patients, Rockpointe and the Potomac Center for Medical Education will offer a series of live CME/ABIM MOC-eligible/ABD MOC-eligible virtual presentations at meetings hosted by state and regional chapters of the American Academy of Dermatology (AAD).
Determining the risk status of newly diagnosed skin cancer patients has major implications for treatment selection. Failure to appropriately assess patient risk can lead to either over- or undertreatment, negatively impacting patient outcomes. Dermatologists stand to benefit from use of new tests designed to aid in diagnosis, staging, risk assessment, and treatment decision-making for melanoma and cSCC. Advances in Skin Cancer Diagnosis: Using New Technologies to Identify High-Risk Patients is an hour-long program geared toward dermatologists, the primary clinicians involved in diagnosis and staging of patients with skin cancer. Presenters will review emerging trends in diagnosis and risk stratification for patients with common skin cancers such as melanoma and cSCC. Discussion topics will include current diagnostic strategies, challenges in risk stratification, and clinical applications for new molecular tests designed to identify high-risk patients and aid in treatment decision-making.
Dates and times (sessions will be added as they are booked)
Thursday, June 17, 2021
8:00 – 9:00 PM ET (7:00 – 8:00 PM CT / 5:00 – 6:00 PM PT)
Hosted by: Wisconsin Dermatological Society
Monday, September 27, 2021
8:00 – 9:00 PM ET (7:00 – 8:00 PM CT / 5:00 – 6:00 PM PT)
Hosted by: Missouri Dermatological Society
Additional date and time*
Tuesday, May 4, 2021
6:00 – 7:00 PM ET (5:00 – 6:00 PM CT / 3:00 – 4:00 PM PT)
Hosted by: Pennsylvania Academy of Dermatology
*This talk is part of a combined meeting with the Pennsylvania Academy of Dermatology. To register for this talk, please click here.
This free educational initiative is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine. At the program’s conclusion, participants should be able to:
- Describe the role of gene expression profiling in the diagnosis of patients with melanoma.
- Evaluate current and emerging staging systems for risk stratification of patients with cSCC.
- Integrate molecular testing platforms to identify patients with melanoma at high risk of recurrence.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education (PCME) and Rockpointe. PCME, which is accredited by the ACCME to provide continuing medical education for physicians, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Successful completion of this CME activity, which includes participation in the evaluation component, enables participants to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.
Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of AMA PRA Category 1 Credits™ annually. Half of these credits must be dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board-certified dermatologists in contributing toward this MOC requirement set forth by the ABD.
There is no fee for this activity, which is supported by an independent educational grant from Castle Biosciences, Inc. To receive credit, participants must register, view the live CME activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, such as managing challenges posed by COVID-19, addressing racial disparities in care, and combating the nation’s opioid crisis. As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy and Medicine. In addition, its popular Medical Education Exchange (MEDX) CME regional meetings include sessions on the basics of quality improvement and alternative payment models, as well as relevant and scientifically accurate sessions on numerous disease states. All sessions include links back to associated National Quality Priorities to reinforce the bigger picture and the triple aim of: 1) improving health and 2) lowering cost to 3) better the patient experience. At Rockpointe, education equals quality.
For more details and to register for Advances in Skin Cancer Diagnosis: Using New Technologies to Identify High-Risk Patients, go to https://www.pathlms.com/rockpointe/courses/28255 or click here.
